Posted by Michael Wonder on 20 Jul 2021
NeuroMetrix receives FDA breakthrough device designation for treatment of fibromyalgia with its wearable neurostimulation technology
20 July 2021 - NeuroMetrix today announced that its Quell device has received breakthrough designation from the U.S. FDA for treating the symptoms of fibromyalgia in adults.
Quell is an advanced, non-invasive, nerve stimulation device that is covered by 18 U.S. utility patents.
